BAY3018250

Phase 2Small molecule

Bayer

BAY3018250 is one of 26 small molecule programs targeting Deep Vein Thrombosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Deep Vein ThrombosisActive, not recruiting

Deep Vein ThrombosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Deep Vein Thrombosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

6 2

Lovenox

Sanofi

Approved

5 3

Xarelto

WWim Janssens

Approved

12 4

Innohep

Alnylam Pharmaceuticals

Approved

1 5

Savaysa

Daiichi Sankyo

Approved

—6

Heparin Sodium

BBaxter Healthcare Corporation

Approved

1 7

Angiomax

BBaxter Healthcare Corporation

Approved

—8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Approved

1 9

Coumadin

AAbbott

Phase 3

5 10

Diosmin

TTanta University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Deep Vein Thrombosis1 trial

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis

Completed· Bayer logo

Bayer·Phase 2·NCT06149520·258 enrolled

Adult1 trial

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

Completed· Bayer logo

Bayer·Phase 1·NCT06562985·39 enrolled

ART1 trial

A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants

Completed· Bayer logo

Bayer·Phase 1·NCT06619483·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BAY3018250. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAY3018250 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAY3018250. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bayer

BAY3018250

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Deep Vein Thrombosis1 trial

Adult1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News